8 completed. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 5 | Completed 5 |
Follow CRC: new trials by email Literature Review of CRC trials Research Report on CRC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors CFT1946, Trametinib, Cetuximab - Solid Tumors, Melanoma | Phase 1 | Completed | C4 Therapeutics, Inc. | 89 | 2022-12-08 | 2025-11-21 |
| Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) E-602, Cemiplimab - Oncology, Melanoma | Phase 1 / Phase 2 | Completed | Palleon Pharmaceuticals, Inc. | 69 | 2022-02-11 | 2025-08-20 |
| JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation JAB-21822 (KRAS G12C inhibitor), Cetuximab (EGFR inhibitor) - Advanced Solid Tumor, NSCLC | Phase 1 / Phase 2 | Completed | Jacobio Pharmaceuticals Co., Ltd. | 29 | 2021-09-03 | 2026-01-13 |
| Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy Cabozantinib, TAS-102 - Colorectal Cancer, Colorectal Carcinoma | Phase 1 | Completed | University of California, Irvine | 15 | 2021-07-16 | 2026-04-24 |
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance] - Solid Tumors, NSCLC | Phase 1 / Phase 2 | Completed | Calithera Biosciences, Inc | 53 | 2019-06-25 | 2022-09-19 |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors NC318 - Advanced or Metastatic Solid Tumors, Lung Cancer | Phase 1 / Phase 2 | Completed | NextCure, Inc. | 109 | 2018-10-01 | 2024-03-08 |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer ompenaclid, FOLFIRI, Bevacizumab - Gastrointestinal Cancer, Gastrointestinal Neoplasms | Phase 1 | Completed | Inspirna, Inc. | 89 | 2018-06-05 | 2025-04-03 |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma JX-594, Irinotecan - Colorectal Carcinoma, CRC | Phase 1 / Phase 2 | Completed | Jennerex Biotherapeutics | 52 | 2012-01-01 | 2026-08-05 |
Colorectal Neoplasms (4) · Melanoma (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Neoplasm Metastasis (2) · Stomach Neoplasms (2) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Neoplasms by Site (7) · Neoplasms (6) · Colonic Diseases (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Rectal Diseases (4) · Gastrointestinal Neoplasms (3) · Lung Diseases (3) · Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3)
Cetuximab (2) · Bevacizumab (1) · CB-839 (1) · Folfox protocol (1) · IFL protocol (1) · Irinotecan (1) · Tablets (1) · cabozantinib (1) · cemiplimab (1) · palbociclib (1) · trametinib (1) · trifluridine tipiracil drug combination (1)
C4 Therapeutics, Inc. (1) · Calithera Biosciences, Inc (1) · Inspirna, Inc. (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · Jennerex Biotherapeutics (1) · NextCure, Inc. (1) · Palleon Pharmaceuticals, Inc. (1) · University of California, Irvine (1)
United States (8) · France (2) · Canada (1) · Germany (1) · Spain (1) · United Kingdom (1)
Derek Jonker, MD (1) · Emil Kuriakose, MD (1) · Farshid Dayyani, MD (1) · Han Myint, MD (1) · James Burke, MD (1) · Robert Wasserman, MD (1)